Brief: Pharvaris Announces Pricing Of $115 Million Underwritten Offering Of Ordinary Shares
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox
U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics
U.S. STOCKS ON THE MOVE-Wendy's, Bristol Myers Squibb, Macy's
Pharvaris jumps as oral therapy for genetic disorder meets main goal in late-stage trial
Brief: Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study
Biopharma firm Pharvaris' Q3 cash at €329 mln, progressing with Phase 3 trials
Pharvaris NV reports results for the quarter ended June 30 - Earnings Summary
Pharvaris NV expected to post a loss of 77 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tesla, Northern Trust, General Dynamics
Drug developer Pharvaris falls after upsized $175 million raise
Brief: Pharvaris Prices Upsized $175 Million Public Offering Of Ordinary Shares, Pre-Funded Warrants
Brief: Pharvaris NV - Expects Rapide-3 Data Announcement In Q4 2025
Brief: Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
Pharvaris NV expected to post a loss of 76 cents a share - Earnings Preview
Pharvaris NV reports results for the quarter ended December 31 - Earnings Summary
Pharvaris NV expected to post a loss of 72 cents a share - Earnings Preview
Brief: Pharvaris Announces Data Highlighting Deucrictibant For The Treatment Of HAE To Be Presented At Upcoming Scientific Meetings
Pharvaris NV reports results for the quarter ended in June - Earnings Summary